Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations: 2024-2025

Historic Cash from Operations for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$80.6 million.

  • Kura Oncology's Cash from Operations fell 85.61% to -$80.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year change of. This contributed to the annual value of $134.3 million for FY2024, which is 207.61% up from last year.
  • Kura Oncology's Cash from Operations amounted to -$80.6 million in Q3 2025, which was down 180.18% from -$28.8 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Cash from Operations peaked at $269.1 million during Q4 2024, and registered a low of -$80.6 million during Q3 2025.
  • Moreover, its 2-year median value for Cash from Operations was -$43.4 million (2024), whereas its average is -$6.7 million.
  • Over the last 5 years, Kura Oncology's Cash from Operations had its largest YoY gain of 32.34% in 2025, and its largest YoY loss of 85.61% in 2025.
  • Kura Oncology's Cash from Operations (Quarterly) stood at $269.1 million in 2024, then plummeted by 85.61% to -$80.6 million in 2025.
  • Its Cash from Operations stands at -$80.6 million for Q3 2025, versus -$28.8 million for Q2 2025 and -$71.9 million for Q1 2025.